AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects

被引：0
|
作者：
Seipelt, I. [1 ]
Gerlach, M. [2 ]
Baasner, S. [1 ]
Blumenstein, L. [1 ]
Mueller, G. [2 ]
Aicher, B. [1 ]
Engel, J. [3 ]
Guenther, E. [4 ]
Teifel, M. [1 ]
机构：
[1] Aeterna Zentaris GmbH, Preclin Dev, Frankfurt, Germany
[2] Aeterna Zentaris GmbH, Med Chem, Frankfurt, Germany
[3] Aeterna Zentaris GmbH, Management Board, Frankfurt, Germany
[4] Aeterna Zentaris GmbH, Alliance Management, Frankfurt, Germany
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)71902-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [41] The Role of PI3K/Akt and ERK in Neurodegenerative Disorders
    Rai, Sachchida Nand
    Dilnashin, Hagera
    Birla, Hareram
    Sen Singh, Saumitra
    Zahra, Walia
    Rathore, Aaina Singh
    Singh, Brijesh Kumar
    Singh, Surya Pratap
    NEUROTOXICITY RESEARCH, 2019, 35 (03) : 775 - 795
  • [42] The Role of PI3K/Akt and ERK in Neurodegenerative Disorders
    Sachchida Nand Rai
    Hagera Dilnashin
    Hareram Birla
    Saumitra Sen Singh
    Walia Zahra
    Aaina Singh Rathore
    Brijesh Kumar Singh
    Surya Pratap Singh
    Neurotoxicity Research, 2019, 35 : 775 - 795
  • [43] Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
    Vincent, Loic
    Thomas, Anne
    Ma, Jianguo
    Clark, Anderson
    Shaw, Jamie
    Guerif, Stephane
    Egile, Coumaran
    Lager, Joanne
    Debussche, Laurent
    Lengauer, Christoph
    Garcia-Echeverria, Carlos
    Ogden, Janet A.
    CANCER RESEARCH, 2011, 71
  • [44] Sensing and Integration of Erk and PI3K Signals by Myc
    Lee, Tae
    Yao, Guang
    Nevins, Joseph
    You, Lingchong
    PLOS COMPUTATIONAL BIOLOGY, 2008, 4 (02)
  • [45] Design, synthesis and antitumor effects of novel benzimidazole derivatives as PI3K inhibitors
    Wu, Wenping
    Li, Sisi
    Chen, Junjie
    Duo, Tena
    Ma, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 95
  • [46] The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
    Won, Jae-Kyung
    Yang, Hee Won
    Shin, Sung-Young
    Lee, Jong Hoon
    Heo, Won Do
    Cho, Kwang-Hyun
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2012, 4 (03) : 153 - 163
  • [47] Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
    Chen, Ming-Huang
    Chiang, Kun-Chun
    Cheng, Chi-Tung
    Huang, Shih-Chiang
    Chen, Yeng-Yang
    Chen, Tsung-Wen
    Yeh, Ta-Sen
    Jan, Yi-Yin
    Wang, Hsi-Ming
    Weng, Jiang-Jie
    Chang, Peter Mu-Hsin
    Liu, Chun-Yu
    Li, Chung-Pin
    Chao, Yee
    Chen, Ming-Han
    Huang, Chi-Ying F.
    Yeh, Chun-Nan
    ONCOTARGET, 2014, 5 (09) : 2372 - 2389
  • [48] Discovery of an irreversible PI3Kα-specific Inhibitor
    Qiao, Lixin
    Nacht, Mariana
    Sheets, Michael P.
    St Martin, Thia
    Labenski, Matthew
    Mazdiyasni, Hormoz
    Zhu, Zhendong
    Chaturvedi, Prasoon
    Bhavsar, Deepa
    Niu, Deqiang
    Westlin, William
    Petter, Russell
    Singh, Juswinder
    CANCER RESEARCH, 2011, 71
  • [49] FDA approves first PI3K inhibitor
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) : 644 - 645
  • [50] FDA approves first PI3K inhibitor
    Nature Reviews Drug Discovery, 2014, 13 (9) : 644 - 645
12345